Eri Hagiwara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eri Hagiwara has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Takashi Ogura
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan
21 shared publications - Tomohisa Baba
13Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan
18 shared publications Shigeru Komatsu
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-Ku, Yokohama, 236-0051, Japan
14 shared publications- Akimasa Sekine
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-Ku, Yokohama, 236-0051, Japan
13 shared publications Ryuichi Nishihira
11 shared publicationsTakeshi Shinohara
10 shared publications
Latest Publications
- 6 September 2024
- Published byĀ ElsevierĀ inĀ Journal of Infection and Chemotherapy
- Vol.Ā 31 Ā (1) , 102515
Clinical characteristics of pulmonary Mycobacterium avium complex disease in patients with interstitial lung disease
- 6 September 2024
- Published byĀ ElsevierĀ inĀ Journal of Infection and Chemotherapy
- Vol.Ā 31 Ā (1) , 102515
Clinical characteristics of pulmonary Mycobacterium avium complex disease in patients with interstitial lung disease
- 13 September 2022
- Published byĀ ElsevierĀ inĀ Journal of Infection and Chemotherapy
- Vol.Ā 29 Ā (1) , 105-108
Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination
- 13 September 2022
- Published byĀ ElsevierĀ inĀ Journal of Infection and Chemotherapy
- Vol.Ā 29 Ā (1) , 105-108
Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination
- Open Access
- 27 January 2022
- Published byĀ Springer NatureĀ inĀ BMC Pulmonary Medicine
- Vol.Ā 22 Ā (1) , 1-8
Usefulness and safety of transbronchial lung cryobiopsy for reassessment of treatment in the clinical course of diffuse parenchymal lung disease
Background: The usefulness and safety of transbronchial lung cryobiopsy (TBLC) for reassessment of diffuse parenchymal lung disease (DPLD) with progression is still unknown. Our purpose was to clarify the usefulness and safety of TBLC for reassessment of DPLD with progression. Methods: This retrospective study included 31 patients with DPLD diagnosed by surgical lung biopsy who progressed in the clinical course and underwent TBLC for reassessment between January 2017 and September 2019 at Kanagawa Cardiovascular & Respiratory Center. Two pulmonologists independently selected the clinical diagnosis, treatment strategy, and confidence level of the treatment strategy based on clinical and radiological information with and without pathological information from TBLC. A consensus was reached among the pulmonologists regarding the clinical diagnosis, treatment strategy, and confidence level of the treatment strategy. Complications of TBLC were also examined. Results: Seven (22.6%), 5 (16.1%), and 6 (19.4%) of clinical diagnosis was changed after TBLC for Pulmonologist A, for Pulmonologist B, and for consensus, respectively. The treatment strategy was changed in 7 (22.6%), 8 (25.9%), and 6 (19.4%) cases after TBLC for Pulmonologist A, for Pulmonologist B and for consensus, respectively. The definite or high confidence level of the consensus treatment strategy was 54.8% (17/31) without TBLC and 83.9% (26/31) with TBLC. There were 6 cases of moderate bleeding, but no other complications were noted. Conclusions: Pathological information from TBLC may contribute to decision-making in treatment strategies for the progression of DPLD, and it may be safely performed.
- 27 January 2022
- Published byĀ Springer NatureĀ inĀ BMC Pulmonary Medicine
- Vol.Ā 22 Ā (1) , 1-8
Open AccessUsefulness and safety of transbronchial lung cryobiopsy for reassessment of treatment in the clinical course of diffuse parenchymal lung disease
Background: The usefulness and safety of transbronchial lung cryobiopsy (TBLC) for reassessment of diffuse parenchymal lung disease (DPLD) with progression is still unknown. Our purpose was to clarify the usefulness and safety of TBLC for reassessment of DPLD with progression. Methods: This retrospective study included 31 patients with DPLD diagnosed by surgical lung biopsy who progressed in the clinical course and underwent TBLC for reassessment between January 2017 and September 2019 at Kanagawa Cardiovascular & Respiratory Center. Two pulmonologists independently selected the clinical diagnosis, treatment strategy, and confidence level of the treatment strategy based on clinical and radiological information with and without pathological information from TBLC. A consensus was reached among the pulmonologists regarding the clinical diagnosis, treatment strategy, and confidence level of the treatment strategy. Complications of TBLC were also examined. Results: Seven (22.6%), 5 (16.1%), and 6 (19.4%) of clinical diagnosis was changed after TBLC for Pulmonologist A, for Pulmonologist B, and for consensus, respectively. The treatment strategy was changed in 7 (22.6%), 8 (25.9%), and 6 (19.4%) cases after TBLC for Pulmonologist A, for Pulmonologist B and for consensus, respectively. The definite or high confidence level of the consensus treatment strategy was 54.8% (17/31) without TBLC and 83.9% (26/31) with TBLC. There were 6 cases of moderate bleeding, but no other complications were noted. Conclusions: Pathological information from TBLC may contribute to decision-making in treatment strategies for the progression of DPLD, and it may be safely performed.
- 1 November 2021
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 59 Ā (6) , 837-844
Asbestos exposure and tuberculous pleurisy as developmental causes of progressive unilateral upper-lung field pulmonary fibrosis radiologically consistent with pleuroparenchymal fibroelastosis
- 1 November 2021
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 59 Ā (6) , 837-844
Asbestos exposure and tuberculous pleurisy as developmental causes of progressive unilateral upper-lung field pulmonary fibrosis radiologically consistent with pleuroparenchymal fibroelastosis
- Open Access
- 12 August 2020
- Published byĀ Springer NatureĀ inĀ BMC Pulmonary Medicine
- Vol.Ā 20 Ā (1) , 1-10
Relationship of flow-volume curve pattern on pulmonary function test with clinical and radiological features in idiopathic pulmonary fibrosis
Background: The flow-volume (FV) curve pattern in the pulmonary function test (PFT) for obstructive lung diseases is widely recognized. However, there are few reports on FV curve pattern in idiopathic pulmonary fibrosis (IPF). In this study, we investigated the relationship between FV curve pattern and clinical or radiological features in IPF. Methods: The FV curves on PFTs and chest high-resolution computed tomography (HRCT) images of 130 patients with IPF were retrospectively evaluated. The FV curves were divided into four groups based on the presence or absence of the convex and concave patterns: convex/concave, non-convex/concave, convex/non-concave, and non-convex/non-concave. Using a computer-aided system, CT honeycombing area (%HA) and subtracted low attenuation area (%sLAA) were quantitatively measured. To assess the distribution of CT findings, the lung area was divided into upper, lower, central, and peripheral areas. The relationships of FV curve patterns with patient characteristics, spirometry results, and quantitative CT findings were evaluated. Results: The patients with convex pattern was identified in 93 (71.5%) and concave pattern in 72 (55.4%). Among the four groups, patients with the convex/non-concave pattern had significantly lower forced vital capacity (FVC) and higher %HA of the upper/peripheral lung area (p = 0.018, and p = 0.005, respectively). The convex/non-concave pattern was a significant predictor of mortality for IPF (hazard ratio, 2.19; p = 0.032). Conclusions: Patients with convex/non-concave pattern in FV curve have lower FVC and poorer prognosis with distinct distribution of fibrosis. Hence, FV curve pattern might be a useful predictor of mortality in IPF.
- 12 August 2020
- Published byĀ Springer NatureĀ inĀ BMC Pulmonary Medicine
- Vol.Ā 20 Ā (1) , 1-10
Open AccessRelationship of flow-volume curve pattern on pulmonary function test with clinical and radiological features in idiopathic pulmonary fibrosis
Background: The flow-volume (FV) curve pattern in the pulmonary function test (PFT) for obstructive lung diseases is widely recognized. However, there are few reports on FV curve pattern in idiopathic pulmonary fibrosis (IPF). In this study, we investigated the relationship between FV curve pattern and clinical or radiological features in IPF. Methods: The FV curves on PFTs and chest high-resolution computed tomography (HRCT) images of 130 patients with IPF were retrospectively evaluated. The FV curves were divided into four groups based on the presence or absence of the convex and concave patterns: convex/concave, non-convex/concave, convex/non-concave, and non-convex/non-concave. Using a computer-aided system, CT honeycombing area (%HA) and subtracted low attenuation area (%sLAA) were quantitatively measured. To assess the distribution of CT findings, the lung area was divided into upper, lower, central, and peripheral areas. The relationships of FV curve patterns with patient characteristics, spirometry results, and quantitative CT findings were evaluated. Results: The patients with convex pattern was identified in 93 (71.5%) and concave pattern in 72 (55.4%). Among the four groups, patients with the convex/non-concave pattern had significantly lower forced vital capacity (FVC) and higher %HA of the upper/peripheral lung area (p = 0.018, and p = 0.005, respectively). The convex/non-concave pattern was a significant predictor of mortality for IPF (hazard ratio, 2.19; p = 0.032). Conclusions: Patients with convex/non-concave pattern in FV curve have lower FVC and poorer prognosis with distinct distribution of fibrosis. Hence, FV curve pattern might be a useful predictor of mortality in IPF.
- 1 December 2019
- Published byĀ ElsevierĀ inĀ Journal of Infection and Chemotherapy
- Vol.Ā 25 Ā (12) , 1026-1030
Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study
- 1 December 2019
- Published byĀ ElsevierĀ inĀ Journal of Infection and Chemotherapy
- Vol.Ā 25 Ā (12) , 1026-1030
Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study
- 1 September 2019
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 57 Ā (5) , 422-429
Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia
- 1 September 2019
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 57 Ā (5) , 422-429
Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia
- 1 January 2019
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 57 Ā (1) , 54-59
Clinical characteristics and early outcomes of patients newly diagnosed with pulmonary Mycobacterium avium complex disease
- 1 January 2019
- Published byĀ ElsevierĀ inĀ Respiratory Investigation
- Vol.Ā 57 Ā (1) , 54-59
Clinical characteristics and early outcomes of patients newly diagnosed with pulmonary Mycobacterium avium complex disease
- 1 October 2018
- Published byĀ ElsevierĀ inĀ European Journal of Radiology
- Vol.Ā 107, 26-32
Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis/dermatomyositis
- 1 October 2018
- Published byĀ ElsevierĀ inĀ European Journal of Radiology
- Vol.Ā 107, 26-32
Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis/dermatomyositis
- 24 April 2018
- Published byĀ WileyĀ inĀ Respirology
- Vol.Ā 23 Ā (11) , 1032-1040
Prognostic factors and disease behaviour of pathologically proven fibrotic nonāspecific interstitial pneumonia
Background and objective: Nonāspecific interstitial pneumonia (NSIP) has heterogeneous characteristics in terms of background, disease behaviour and prognosis. This study of fibrotic NSIP (fāNSIP) aimed to elucidate prognosis and disease behaviour from the viewpoint of clinical background and determine whether longāterm change of pulmonary function could provide useful prognostic information.Methods: We analysed the medical records of 157 consecutive patients diagnosed with fāNSIP by surgical lung biopsy. Disease behaviour was categorized into two groups depending on longāterm change of pulmonary function: progressive type (relative ā„5%/year decline in the slope of forced vital capacity and/or relative ā„7.5%/year decline in the slope of %diffusing capacity of lung carbon monoxide) or stable type. Predictors of disease behaviour and prognosis were determined using logistic and Cox regression models.Results: Our fāNSIP cohort included interstitial pneumonia with autoimmune features (IPAF) (36.9%), idiopathic (nonāIPAF) (22.3%) and connective tissue diseaseāassociated interstitial lung disease (40.8%). Multivariate analysis showed that idiopathic (nonāIPAF) fāNSIP and progressive type disease were negative prognostic factors of mortality. Poor treatment response at 1 year was an independent predictor of progressive type disease, but was not related to survival. In terms of disease behaviour based on pulmonary function change, some patients with IPAF fāNSIP showed a progressive course.Conclusion: Although an IPAF diagnosis was useful for identifying good prognosis in idiopathic fāNSIP, some idiopathic fāNSIP patients with or without IPAF showed progressive disease despite therapy. The definition of progressive type disease may be useful in clinical decisionāmaking when determining therapy for fāNSIP.
- 24 April 2018
- Published byĀ WileyĀ inĀ Respirology
- Vol.Ā 23 Ā (11) , 1032-1040
Prognostic factors and disease behaviour of pathologically proven fibrotic nonāspecific interstitial pneumonia
Background and objective: Nonāspecific interstitial pneumonia (NSIP) has heterogeneous characteristics in terms of background, disease behaviour and prognosis. This study of fibrotic NSIP (fāNSIP) aimed to elucidate prognosis and disease behaviour from the viewpoint of clinical background and determine whether longāterm change of pulmonary function could provide useful prognostic information.Methods: We analysed the medical records of 157 consecutive patients diagnosed with fāNSIP by surgical lung biopsy. Disease behaviour was categorized into two groups depending on longāterm change of pulmonary function: progressive type (relative ā„5%/year decline in the slope of forced vital capacity and/or relative ā„7.5%/year decline in the slope of %diffusing capacity of lung carbon monoxide) or stable type. Predictors of disease behaviour and prognosis were determined using logistic and Cox regression models.Results: Our fāNSIP cohort included interstitial pneumonia with autoimmune features (IPAF) (36.9%), idiopathic (nonāIPAF) (22.3%) and connective tissue diseaseāassociated interstitial lung disease (40.8%). Multivariate analysis showed that idiopathic (nonāIPAF) fāNSIP and progressive type disease were negative prognostic factors of mortality. Poor treatment response at 1 year was an independent predictor of progressive type disease, but was not related to survival. In terms of disease behaviour based on pulmonary function change, some patients with IPAF fāNSIP showed a progressive course.Conclusion: Although an IPAF diagnosis was useful for identifying good prognosis in idiopathic fāNSIP, some idiopathic fāNSIP patients with or without IPAF showed progressive disease despite therapy. The definition of progressive type disease may be useful in clinical decisionāmaking when determining therapy for fāNSIP.